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Abstract Neuroprotection for glaucoma is a therapeutic approach that aims to
prevent optic nerve damage or cell death. An appropriate drug that reaches
an adequate concentration across the blood retinal barrier is expected
to shield the retina in glaucoma. Several in vitro and in vivo attempts in
experimental models indicate the possibility of successful neuroprotection.
However, clinical trials might not show the same level of neuroprotection as a
result of subtherapeutic concentrations of the drug in the eye. The study
by Zhong et al. in this issue ofDrugs in R&D could not attribute the observed
improvement in visual field indices to any one of the individual active
constituents of Erigeron breviscapus (vant.) Hand. Mazz. (EBHM). One of
the major constituents of EBHM is scutellarin, which is known to have poor
oral bioavailability and an unclear ability to penetrate inside the eye. There-
fore, before recognizing EBHM as a neuroprotectant in glaucoma for further
clinical studies and practice, its active constituents and their pharmacokine-
tics (systemic as well as ocular) need to be explored.
Neuroprotection as a pharmacological strat-
egy to shield retinal ganglion cell death has been a
popular approach adopted by many researchers.
Yet, its effectiveness in preventing retinal gang-
lion cell death and thereby preserving vision in
patients with primary open-angle glaucoma has
not been demonstrated.[1]
Mitochondria are abundant in the unmyelin-
ated part of the retinal ganglion cell axons tomeet
the higher energy demand for nerve conduction
and for the maintenance of optimum neuronal
function.[2] Ischemia to the optic nerve head
region can cause ganglion cell death at different
rates. Therefore, effective intraocular pressure
(IOP) control and blocking intracellular death
triggers are both viable options. The right phar-
macologic agent with a meaningful intraocular
penetration would rationalize the neuroprotect-
ion strategy in glaucoma.
For the last three decades, several attempts
have been made to establish a successful neuro-
protectant for glaucoma using various in vitro
and in vivo models. A comprehensive PubMed
search with the MeSH terms ‘‘glaucoma’’ and
‘‘neuroprotection’’ revealed the following com-
pounds, factors and plant extracts: NMDA re-
ceptor antagonists (memantine, dexanabinol), an
a2-adrenergic receptor agonist (brimonidine),
an a1- and b-adrenergic receptor antagonist with
a nitric oxide donor (nipradilol), an angiotensin
II type 1 receptor blocker (candesartan), a pros-
taglandin-related compound (tafluprost), calcium
channel blockers (nilvadipine and cilnidipine),
a sodium channel blocker (phenytoin), a dual
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sodium and calcium channel blocker (NS-7),
a choline precursor (citicoline), a tetracycline
(minocycline), an anti-inflammatory agent (aspi-
rin [acetylsalicylic acid]), an endothelin antagon-
ist (sulfisoxazole), an inducible nitric oxide synthase
inhibitor (aminoguanidine), a-tocopherol, and
vinpocetine.
Endogenous compounds or their analogs,
such as (endo)cannabinoids, granulocyte-colony
stimulating factor (G-CSF), hematopoietic cyto-
kine (erythropoietin), nerve growth factor, natu-
ral amino acid (taurine), glial cell line-derived
neurotrophic factor and estrogen analogs (ZYC-
1, ZYC-3), were also scrutinized.
Plant extracts and derived compounds, such
as Ginkgo biloba extract, carotenoids (xantho-
phylls), epigallocatechin-gallate, cannabinoids,
ferulic acid from Ligusticum wallichii, a muscarnic
agonist (pilocarpine), a lignophenol derivative
from bamboo lignin (Lig-8), aloe-emodin meta-
bolites, Lycium barbarum, red wine-polyphenols
(resveratrol),Erigeron breviscapus, flavonoids, and
spider venomderived 2-amino-5-ureidopentanamide
from Parawixia bistriata, were suggested as po-
tential candidates and some of them were also
evaluated using in vitro and in vivo experimental
models for neuroprotection in glaucoma.
Although there is good laboratory evidence
for neuroprotection in glaucoma by many agents,
proof from randomized clinical trials is lacking.[3]
The reasons for the failure of any such clinical
attempts are unclear as many of the results from
these trials have not been published.
A potential neuroprotectant compound needs
to effectively cross the blood retinal barrier
(BRB) into the eye. Agents given systemically,
such as antimicrobials, seldom reach effective
concentrations in the uninflammed eye.[4] For
that reason, a neuroprotectant may require mul-
tiple doses at frequent intervals over a longer
duration to achieve a significant concentration
in the eye. In addition to the plasma kinetics of
a compound, its vitreous disposition is also im-
portant in determining its therapeutic action. It
is currently well recognized that the presence of
drug transporters in the BRB are responsible for
the efflux of the intravitreally injected drug and
for resisting the influx of the drug into the eye
when it is given systemically. The presence of P-
glycoprotein efflux transporters, cationic/anionic
transporters, and other transporters in the BRB
that resist the entry of systemically given sub-
strates is well documented.[5-7] Hence, for any
predictable outcome in retinal neuroprotection,
the ocular pharmacokinetic profile of the drug
needs to be explored before initiating a clinical
trial.
Systemic treatment with memantine of ex-
perimental glaucoma in monkeys showed that it
was safe and effective in reducing the functional
loss of the retina, although it had no effect on
IOP. This study concluded that peak plasma
concentration (Cmax) of memantine reached
1 mmol/L at 4–15 months after the initiation of
an oral dose of 4mg/kg/day and similar levels
were also observed in the vitreous humour after
16 months.[8] Surprisingly, memantine, which is
approved for the treatment of Alzheimer’s dis-
ease, has failed to show any significant improve-
ment in glaucoma in subsequent clinical trials as a
neuroprotectant.[9]
A single 20mg dose of memantine resulted in a
Cmax of 0.14 mmol/L in healthy human volun-
teers, a time to Cmax of 6.9 hours and a half-life
of 62 hours.[10] A human study conducted
by Kornhuber and Quack[11] reported that a
20mg/day oral dose of memantine over 14 days
resulted in concentrations of 0.37 mmol/L in the
plasma and 0.207 mmol/L in the cerebrospinal
fluid (CSF) at 2–3 hours after the last mainten-
ance dose, and a CSF to serum ratio of 0.55 was
proposed. A target concentration of memantine
1 mmol/L is expected to prevent excitotoxicity in
neurons.[12] The failure of memantine in the
clinical trial for neuroprotection in glaucoma
might have been due to an inadequate concen-
tration of memantine in the vitreous after the oral
dose of 20mg/day.
The randomized, double-blind, clinical trial
reported by Zhong et al.[13] in this issue of Drugs
in R&D concluded that the Chinese traditional
herb Erigeron breviscapus (vant.) Hand. Mazz.
(EBHM) showed a partial protective effect in
the visual field of glaucoma patients with
controlled IOP. Breviscapine is a commercially
produced plant extract from the Chinese herb
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EBHM. Scutellarin is a flavone glucuronide
(5,6,40-trihydroxyflavone-7-O-glucoronide) and
is reported to be the main active component of
EBHM.[14] The percentage of scutellarin varies
according to the source of production. In ex-
perimental studies, it has been reported to have
estrogenic and neuroprotective properties.[15]
Breviscapine has been reported to attenuate
neuroapoptosis and regulate the protein ex-
pression related to apoptosis after transient focal
cerebral ischemia at a dose of 50–100mg/kg
in rats.[16] Neuroprotective effects of scutellarin
on brain ischemic injury-induced apoptosis have
been reported to be associated with inhibition
of PARP-dependent mitochondrial dysfunction
and subsequent translocation of the apoptosis-
inducing factor pathway.[17]
Rat brain drug distribution studies showed
that 22.3% of orally and 29.18% of tail vein ad-
ministered radiolabeled breviscapine reached the
brain tissues when it was administered at a dose
of 0.4mg/kg.[18] Interestingly, an experimental
study in rats also reported that protective effects
of scutellarin on cardiovascular and cerebrovas-
cular ischemia were better than those of the ex-
tract mixture (breviscapine).[19] Another study
reported that the relative bioavailabilities of or-
ally administered scutellarin and scutellarein
conjugates in rats were very low (<11%).[20]
In this issue of Drugs in R&D, Zhong et al.[13]
could not attribute the observed activity to any
one of the individual active constituents of EBHM.
They have correlated the activity to 40-hydro-
scutellarein, 40-hydrobaicalein-7-b-D-plamyagin,
40-hydroscutellarein-7-b-D-glycuron methyl es-
ter, pyromeconic acid, and several kinds of fla-
vones and flavonoids. Chen et al.[21] reported that
after a single oral administration of scutellarin
60mg to 20 healthy subjects, plasma concen-
trations of scutellarin and its major metabolite
(isoscutellarin) were found to reach a mean Cmax
of <5.0 and 87 ng/mL, respectively. They have
also indicated that after hydrolysis in the gastro-
intestinal system by bacterial enzymes, the agly-
cone of scutellarin (scutellarein) was detected in
serum as glucuronic acid conjugates, which
showed regioselectivity and species difference. Con-
sidering the limited oral absorption of its major
constituent (scutellarin), EBHM needs rigorous
analysis regarding the active constituent(s) that
get absorbed into the systemic circulation and, in
turn, reach the vitreous humor for the projected
activity.
Before promoting EBHMas a neuroprotectant
for glaucoma and commencing with long-term
studies, it is essential to identify the active con-
stituent(s) and to determine whether the com-
pounds have the ability to cross the closed gateways
of the BRB to reach an effective concentration to
shield the retina.
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